StreetAlpha.app
Home › Stocks › STXS

Stereotaxis, Inc. (STXS)

$0.94
▼ −6.71%
LAST CLOSE · NOV 20

Stereotaxis makes electromedical systems and disposable devices that physicians use in interventional procedures. It last closed at $0.94 on Nov 20, down 6.71% on the day. The next earnings report for STXS is expected around Mon, Mar 8, 2027, after the close. For the quarter ended Sep 2026, STXS reported EPS of -$0.07 on revenue of $8.9M, with revenue up 19.6% from a year ago. Over its last 8 reports the stock moved an average of 6.0% the session after earnings. Over the last 12 months STXS insiders bought $136K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is STXS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold STXS.

Key Stats

Last 12 months
Results
Revenue
$31.5M
+4.8% vs a year ago
Net income
−$22.3M
−70.9% margin
EPS (diluted)
−$0.24
Free cash flow
−$15.5M
−49.2% margin
Valuation
Market cap
$95.0M
100.9M shares
P/E
–
No P/E while losing money
Price to sales
3.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$4.0M
At Sep 30
Debt
$2.5M
At Sep 30
Shareholder equity
$21.4M
Shares outstanding
100.9M
At Oct 31
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $35.0M$35.0MFY2021FY2022: $28.1M$28.1MFY2022FY2023: $26.8M$26.8MFY2023FY2024: $26.9M$26.9MFY2024FY2025: $32.4M$32.4MFY2025

From STXS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Mar 8
Estimated date · After the close
Reported EPS
-$0.07
Quarter ended Sep 2026
Year ago EPS
-$0.07
Same quarter last year
Revenue
$8.9M
+19.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.09Dec '24Mar 2025: -$0.07Mar '25Jun 2025: -$0.05Jun '25Sep 2025: -$0.07Sep '25Dec 2025: -$0.06Dec '25Mar 2026: -$0.06Mar '26Jun 2026: -$0.05Jun '26Sep 2026: -$0.07Sep '26Latest -$0.07
Revenue by quarter
Dec 2024: $6.3MDec '24Mar 2025: $7.5MMar '25Jun 2025: $8.8MJun '25Sep 2025: $7.5MSep '25Dec 2025: $8.6MDec '25Mar 2026: $6.3MMar '26Jun 2026: $7.7MJun '26Sep 2026: $8.9MSep '26Latest $8.9M
How STXS moved after its last 8 reports
Average move the session after a report ±6.0%
Nov 10, 2026After the close−12.6%
Aug 11, 2026After the close−4.1%
May 12, 2026After the close−3.6%
Mar 9, 2026After the close−4.8%
Nov 12, 2025Time not announced−14.7%
Jul 17, 2025Time not announced−0.4%
May 12, 2025After the close+1.9%
Mar 3, 2025Time not announced−5.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on STXSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on STXS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on STXS

Technical Analysis

STXS · as of the Nov 20 close · updated each morning
Downtrend

The stock is 0% below its 20 day and 15% below its 50 day average. It is 69% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 47). The nearest support is the Pivot S1 at $0.89, and the nearest resistance the Pivot at $0.95.

Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 10.4%/day
Key levels
$2.8652 week high+204.3%
$1.60200 day average+70.2%
$1.27100 day average+35.1%
$1.0950 day average+16.0%
$1.04Swing high (Oct 23)+10.6%
$1.00Pivot R1+6.4%
$0.9520 day average+1.1%
$0.95Pivot+1.1%
$0.94Last close
$0.89Pivot S1−5.3%
$0.8052 week low−14.9%
$0.80Swing low (Nov 3)−14.9%
Indicators
RSI (14)46.85Middle of its rangeNeutral
MACD-0.04Above its signal lineBullish
Stochastic39.1Middle of its rangeNeutral
ADX (14)29.0Trending down
Williams %R-66.5Oversold below −80, overbought above −20Neutral
CCI (20)3.4Oversold below −100, overbought above 100Neutral
Rate of change−13.6%Change over 10 sessionsBearish
ATR (14)$0.10Typical daily range, 10.4% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for STXS

What happened before

See how STXS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow STXS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How STXS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for STXSHow many large options trades hit STXS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

STXS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●44 buying vs 47 selling
  • ▼Held by funds -1.9 pts
  • ▼Funds holding -7
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding102109−6.4%
In funds' top 1013−66.7%
Held by funds40.8%42.7%−1.9 pts
New / increased10 / 3413 / 44−22.8%
Reduced / sold out30 / 1722 / 16+23.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See STXS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

STXS Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$136K3 buys · 3 insiders
Sold$00 sales · 0 insiders
Cluster buy: 3 insiders bought $136K between Nov 16 and Nov 17.
2026-11 bought $136KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17Paul J IsaacDirectorBuy13,300$0.82$11K
Nov 17Arun Swarup MenawatDirectorBuy121,561$0.82$100K
Nov 17David BenferDirectorBuy30,000$0.83$25K
Nov 17, 2025Paul J IsaacDirectorBuy30,000$2.22$67K
Mar 10, 2025Paul J IsaacDirectorBuy38,000$1.81$69K
Mar 7, 2025Paul J IsaacDirectorBuy24,788$1.81$45K
Every insider buy and sale for STXS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See STXS insider trades →

From SEC Form 4 filings by STXS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether STXS is in one of them and how their past STXS trades turned out.

STXS in the AI portfolios
Loading…

STXS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered STXS in an article yet. Here's the latest on the wider market.

STXS in the news

About Stereotaxis

Stereotaxis is a medical technology company based in St. Louis, Missouri. It makes electromedical systems and disposable interventional devices that physicians use to perform medical procedures. Its main customers are hospitals and the physicians who practice in them. Its product lines include Niobe, Genesis RMN, and Odyssey, and it works with business partners and seeks regulatory approval for additional disposable devices.

Headquarters
St.Louis, MO